Pay in 4 interest-free payments of $6.22 Learn more
Ships within 48 hours · Estimated delivery Jul 30 - Aug 4
van de Wetering, M
If you miss a dose and the next scheduled dose is more than 4 days away, take the missed dose as soon as possible
Financial Dominance & Operating Leverage Q3 2025 Financial Highlights Revenue: $17.6B (+54% YoY) Non-GAAP EPS: $7.02 (+495% YoY) Gross Margin: 83.6% (+1.4 pts) Operating Cash: Strong (Record levels) Full-Year 2025 Guidance (Raised) Revenue: $63.0-63.5B (up from $60-62B) Non-GAAP EPS: $23.00-23.70 (up from $21.75-23.00) Profitability Metrics Return on Equity (ROE): ~74-88% (exceptional capital efficiency) Gross Margin: 83.6% (among highest in pharma) R&D Investment: $3.47B in Q3 (+27% YoY) fueling future growth These metrics place Lilly among the most efficient, profitable companies in the S&P 500
Conclusion When it comes to weight management, safety and personalization should always come first
US$ 20.50
:max_bytes(150000):strip_icc()/benefits-of-glutathione-89457_final-01-502464fe91b2444285b0cccf8cb0a33c.png)
US$ 24.25
US$ 25.84
US$ 20.57
US$ 22.95
US$ 20.48
US$ 28.04
US$ 26.46
